XML 140 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
Other disclosures (Tables)
 12 Months Ended
Dec. 31, 2021
Additional information [abstract]  
Share-based payment expensed in the income statement
Share-based payment expensed in the income statement
DKK million202120202019
Restricted stock units to employees18918948
Long-term share-based incentive programme (Management Board)1
23416286
Long-term share-based incentive programme (management group below Management Board)598436195
Shares allocated to individual employees193634
Share-based payment expensed in the income statement1,040823363
1. In 2021, Novo Nordisk introduced a new share-based compensation programme with terms, which amortises the grant date valuation over three years (2018, 2019 and 2020 were amortised over four years). The 2021 expense includes amortisation of the 2018, 2019, 2020 and 2021 programmes.
General terms and conditions of launched programmes
General terms and conditions of launched programmes
Restricted stock units to employeesShares for Management BoardShares for management group below Management BoardShares allocated to individual employees
202120202019202120202019202120202019202120202019
Number of shares awarded in the year (million)— — 2.1 0.5 0.4 0.5 1.6 1.0 1.3 0.1 0.0 0.2 
Value per share at launch (DKK)— — 307 423 411 298 423 411 298 538 391 311 
Total market value at launch (DKK million)— — 660 223 152 152 649 416 387 71 17 48 
Performance and vesting period
2019 to 20232021 to 20232020 to 20232019 to 20222021 to 20232020 to 20232019 to 20222021 to 20242020 to 20232019 to 2022
Allocated to recipientsFeb 2023Feb 2024Feb 2024Feb 2023Feb 2024Feb 2024Feb 2023202420232022
Amortisation period— — 3.5 years3 years4 years4 years3 years4 years4 years3 years3 years3 years
Outstanding restricted stock units
Outstanding restricted stock units (million)Restricted stock units to employeesShares for Management BoardShares for management group below Management BoardShares allocated to individual employeesTotal
202120202019202120202019202120202019202120202019202120202019
Outstanding at the beginning of the year2.1 2.1 1.5 1.8 1.3 1.2 4.5 3.2 2.7 0.2 0.3 0.2 8.6 6.9 5.6 
Released allocated shares(0.1)(0.0)(1.4)(0.3)(0.1)(0.4)(0.6)(0.2)(0.7)(0.1)(0.1)(0.1)(1.1)(0.4)(2.6)
Cancelled allocated shares— — (0.1)— (0.0)(0.0)(0.3)(0.1)(0.1)(0.0)(0.0)(0.0)(0.3)(0.1)(0.2)
Allocated in the year— — 2.1 0.5 0.4 0.5 1.6 1.0 1.3 0.1 0.0 0.2 2.2 1.4 4.1 
Performance adjustment1
— — — 0.2 0.2 — 0.3 0.6 — 0.0 — — 0.5 0.8 — 
Outstanding at the end of the year2.0 2.1 2.1 2.2 1.8 1.3 5.5 4.5 3.2 0.2 0.2 0.3 9.9 8.6 6.9 
1. The number of shares for Management Board and management group below Management board has been adjusted as the financial and non-financial targets set by the Board are expected to be exceeded for the 2021 programme. The number of shares for Management Board and management group below Management board has been adjusted as the sales growth target set by the Board for the 2018 programme is exceeded and is expected to be exceeded for the 2019 and 2020 programmes.
Contractual obligations not recognised in the balance sheet
Contractual obligations not recognised in the balance sheet
DKK millionCurrentNon-currentTotal
2021
Leases1
145 636 781
Research and development obligations4,196 6,357 10,553
Research and development – potential milestone payments2
771 4,220 4,991
Commercial product launch – potential milestone payments2
— 5,966 5,966
Purchase obligations relating to investments in property, plant and equipment545 — 545
Other purchase obligations13,407 5,998 19,405
Total obligations not recognised in the balance sheet19,064 23,177 42,241
2020
Leases1
152 612 764 
Research and development obligations2,733 4,502 7,235 
Research and development – potential milestone payments2
205 3,878 4,083 
Commercial product launch – potential milestone payments2
— 6,105 6,105 
Purchase obligations relating to investments in property, plant and equipment339 — 339 
Other purchase obligations7,528 4,535 12,063 
Total obligations not recognised in the balance sheet10,957 19,632 30,589 
1. Predominantly relates to estimated variable property taxes, leases committed but not yet commenced and low value assets.
2. Potential milestone payments are associated with uncertainty as they are linked to successful achievements in research activities.
Fair value of recognized assets and liabilities
The provisional fair value of recognised assets and liabilities is as follows:

DKK million2021
Intellectual property rights18,687
Other intangible assets24
Financial assets31
Cash3,033
Deferred tax assets/liabilities, net(3,480)
Other net assets(607)
Net identifiable assets acquired17,688
Goodwill4,346
Purchase price22,034
Settlement of pre-existing relationship(145)
Fair value of existing shareholdings(573)
Consideration transferred21,316
Cash acquired(3,033)
Cash used for acquisition of businesses18,283
Material transactions with related parties
Material transactions with related parties
DKK million202120202019
Novo Holdings A/S
Purchase of Novo Nordisk B shares6,6955,9634,894
Dividend payment to Novo Holdings A/S6,1445,7675,580
NNIT Group
Services provided by NNIT593775941
Dividend payment from NNIT(4)(18)(20)
Novozymes Group
Services provided by Novo Nordisk(116)(113)(132)
Services provided by Novozymes7872103
CS Solar Fund XIV
Purchase of shares by Novo Nordisk——97
Liability for capital commitment1
——389
Distribution by CS Solar Fund XIV——(385)
1. The liability disclosed for 2019 related to capital commitment was paid in 2020
     (DKK 392 million).
Fee to statutory auditors
DKK million202120202019
Statutory audit262626
Audit-related services334
Tax advisory services4911
Other services444
Total fee to statutory auditors374245
Companies in the Novo Nordisk Group
Activity: • Sales and marketing• Production
• Research and development• Services/investments
Company and countryPercentage of shares ownedActivity
Parent company
Novo Nordisk A/S, Denmark••••
Subsidiaries by geographical area
North America Operations
Novo Nordisk Canada Inc., Canada100•
Novo Nordisk Inc., United States100•
Novo Nordisk North America Operations A/S, Denmark100•
Novo Nordisk Pharmaceutical Industries LP, United States100•
Novo Nordisk Pharmatech US, Inc., United States100•
Novo Nordisk Pharma, Inc., United States100•
Novo Nordisk Research Center Indianapolis, Inc., United States100•
Novo Nordisk Research Center Seattle, Inc., United States100•
Novo Nordisk US Bio Production, Inc., United States100•
Novo Nordisk US Commercial Holdings, Inc., United States100•
Novo Nordisk US Holdings Inc., United States100•
Corvidia Therapeutics, Inc., United States100•
Dicerna Pharmaceuticals, Inc., United States100•
Emisphere Technologies, Inc., United States100•
International Operations
Novo Nordisk Pharmaceuticals A/S, Denmark100•
Novo Nordisk Pharma Operations A/S, Denmark100••
Novo Nordisk Region AAMEO and LATAM A/S, Denmark100•
Novo Nordisk Region Europe A/S, Denmark100•
Novo Nordisk Region Japan & Korea A/S, Denmark100•
EMEA
Aldaph SpA, Algeria100••
Novo Nordisk Pharma GmbH, Austria100•
S.A. Novo Nordisk Pharma N.V., Belgium100•
Novo Nordisk Pharma d.o.o., Bosnia and Herzegovina100•
Novo Nordisk Pharma EAD, Bulgaria100•
Novo Nordisk Hrvatska d.o.o., Croatia100•
Novo Nordisk s.r.o., Czech Republic100•
Novo Nordisk Denmark A/S, Denmark100•
Novo Nordisk Pharmatech A/S, Denmark100••
Novo Nordisk Egypt LLC, Egypt100•
Novo Nordisk Farma OY, Finland100•
Novo Nordisk, France100•
Novo Nordisk Production SAS, France100•
Novo Nordisk Pharma GmbH, Germany100•
Novo Nordisk Hellas Epe., Greece100•
Novo Nordisk Hungária Kft., Hungary100•
Neotope Neuroscience Limited, Ireland100•
Company and countryPercentage of shares ownedActivity
Novo Nordisk Limited, Ireland100•
Novo Nordisk Ltd, Israel100•
Novo Nordisk S.P.A., Italy100•
Novo Nordisk Kazakhstan LLP, Kazakhstan100•
Novo Nordisk Kenya Ltd., Kenya100•
Novo Nordisk Pharma SARL, Lebanon100•
UAB Novo Nordisk Pharma, Lithuania100•
Novo Nordisk Farma dooel, North Macedonia100•
Novo Nordisk Pharma SAS, Morocco100•
Novo Nordisk B.V., Netherlands100•
Novo Nordisk Finance (Netherlands) B.V., Netherlands100•
Novo Nordisk Pharma Limited, Nigeria100•
Novo Nordisk Norway AS, Norway100•
Novo Nordisk Pharmaceutical Services Sp. z o.o., Poland100•
Novo Nordisk Pharma Sp.z.o.o., Poland100•
Novo Nordisk Comércio Produtos Farmacêuticos Lda., Portugal100•
Novo Nordisk Farma S.R.L., Romania100•
Novo Nordisk Limited Liability Company, Russia100•
Novo Nordisk Production Support LLC, Russia100•
Novo Nordisk Saudi for Trading, Saudi Arabia100•
Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Serbia100•
Novo Nordisk Slovakia s.r.o., Slovakia100•
Novo Nordisk, d.o.o., Slovenia100•
Novo Nordisk (Pty) Limited, South Africa100•
Novo Nordisk Pharma S.A., Spain100•
Novo Nordisk Scandinavia AB, Sweden100•
Novo Nordisk Health Care AG, Switzerland100••
Novo Nordisk Pharma AG, Switzerland100•
Novo Nordisk Tunisie SARL, Tunisia100•
Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Turkey100•
Novo Nordisk Ukraine, LLC, Ukraine100•
Novo Nordisk Pharma Gulf FZE, United Arab Emirates100•
Novo Nordisk Holding Limited, United Kingdom100•
Novo Nordisk Limited, United Kingdom100•
Ziylo Limited, United Kingdom100•
Region China
Novo Nordisk (China) Pharmaceuticals Co., Ltd., China100••
Novo Nordisk (Shanghai) Pharma Trading Co., Ltd., China100•
Beijing Novo Nordisk Pharmaceuticals Science & Technology Co., Ltd., China100•
Novo Nordisk Region China A/S, Denmark100•
Novo Nordisk Hong Kong Limited, Hong Kong100•
Novo Nordisk Pharma (Taiwan) Ltd., Taiwan100•
Company and countryPercentage of shares ownedActivity
Rest of World
Novo Nordisk Pharma Argentina S.A., Argentina100•
Novo Nordisk Pharmaceuticals Pty. Ltd., Australia100•
Novo Nordisk Pharma (Private) Limited, Bangladesh100•
Novo Nordisk Produção Farmacêutica do Brasil Ltda., Brazil100•
Novo Nordisk Farmacêutica do Brasil Ltda., Brazil100•
Novo Nordisk Farmacéutica Limitada, Chile100•
Novo Nordisk Colombia SAS, Colombia100•
Novo Nordisk India Private Limited, India100•
Novo Nordisk Service Centre (India) Pvt. Ltd., India100•
PT. Novo Nordisk Indonesia, Indonesia100•
Novo Nordisk Pars, Iran100••
Novo Nordisk Pharma Ltd., Japan100••
Novo Nordisk Pharma (Malaysia) Sdn Bhd, Malaysia100•
Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Malaysia100•
Novo Nordisk Mexico S.A. de C.V., Mexico100•
Novo Nordisk Pharmaceuticals Ltd., New Zealand100•
Novo Nordisk Pharma (Private) Limited, Pakistan100•
Novo Nordisk Panama S.A., Panama100•
Novo Nordisk Peru S.A.C., Peru100•
Novo Nordisk Pharmaceuticals (Philippines) Inc., Philippines100•
Novo Nordisk Pharma (Singapore) Pte Ltd., Singapore100•
Novo Nordisk India Holding Pte Ltd., Singapore100•
Novo Nordisk Pharma Korea Ltd., South Korea100•
Novo Nordisk Lanka (PVT) Ltd, Sri Lanka100•
Novo Nordisk Pharma (Thailand) Ltd., Thailand100•
Novo Nordisk Venezuela Casa de Representación C.A., Venezuela100•
Other subsidiaries and associated companies
NNE A/S, Denmark100•
NNIT A/S, Denmark18•
CS Solar Fund XIV, LLC, United States99•